Dianthus Therapeutics Ownership & Insider Activity

Dianthus Therapeutics (DNTH) institutional and insider ownership, recent insider transactions and ownership breakdown.

Insiders own 0.2% of shares outstanding. Institutional investors hold 79.1%.

Shares Outstanding

55.934M

Shares Float

48.757M

Insider Shares Owned

84.292K

Insider % Owned

0.2%

Institutional Shares Held

44.220M

Institutional % Held

79.1%

Ownership Breakdown

Net Insider Activity by Month

Dianthus Therapeutics Insider Transactions (Last 6 Months)

Date	Insider	Title	Type	Shares	Price	Value
Sep 1, 2026	Simrat Randhawa	EVP, HEAD R&D	SELL-OPTIONS	—	$63.52	$2.0M
Aug 19, 2026	Simon Read	—	SELL-OPTIONS	—	$67.95	$276K
Aug 10, 2026	Anne McGeorge	—	SELL-OPTIONS	—	$60.76	$748K
Aug 10, 2026	Simon Read	—	SELL-OPTIONS	—	$63.96	$253K
Aug 7, 2026	Adam Veness	SVP, GENERAL COUNSEL AND SEC.	SELL-OPTIONS	—	$64.16	$1.9M
Aug 7, 2026	Marino Garcia	CEO AND PRESIDENT	SELL-OPTIONS	—	$58.27	$16.5M
Jul 9, 2026	Ryan Savitz	EVP, CFO & CBO	SELL-OPTIONS	—	$61.40	$2.5M
Jun 17, 2026	Adam Veness	SVP, GENERAL COUNSEL AND SEC.	SELL-OPTIONS	—	$49.34	$1.9M
Jun 1, 2026	Simrat Randhawa	EVP, HEAD R&D	SELL-OPTIONS	—	$54.74	$1.9M
May 8, 2026	Paula Soteropoulos	—	SELL-OPTIONS	—	$46.95	$46K
Apr 9, 2026	Ryan Savitz	EVP, CFO & CBO	SELL-OPTIONS	—	$53.86	$592K
Mar 31, 2026	Ryan Savitz	EVP, CFO & CBO	SELL-OPTIONS	—	$47.37	$8.1M
Mar 31, 2026	Paula Soteropoulos	—	SELL-OPTIONS	—	$44.27	$43K
Mar 24, 2026	Paula Soteropoulos	—	SELL-OPTIONS	—	$43.24	$1.9M